825 related articles for article (PubMed ID: 32536199)
1. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
3. Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes.
Gronda EG; Vanoli E; Iacoviello M; Urbinati S; Caldarola P; Colivicchi F; Gabrielli D
Heart Fail Rev; 2023 May; 28(3):723-732. PubMed ID: 35098383
[TBL] [Abstract][Full Text] [Related]
4. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
5. Are SGLT2 Inhibitors Ready for Prime Time for CKD?
Pecoits-Filho R; Perkovic V
Clin J Am Soc Nephrol; 2018 Feb; 13(2):318-320. PubMed ID: 28893920
[No Abstract] [Full Text] [Related]
6. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitors in people with and without T2DM.
Khunti K
Nat Rev Endocrinol; 2021 Feb; 17(2):75-76. PubMed ID: 33293703
[No Abstract] [Full Text] [Related]
8. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
O'Meara E; Verma S
Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
[TBL] [Abstract][Full Text] [Related]
10. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
11. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
Brown E; Wilding JPH; Alam U; Barber TM; Karalliedde J; Cuthbertson DJ
Ann Med; 2021 Dec; 53(1):2072-2089. PubMed ID: 33107349
[TBL] [Abstract][Full Text] [Related]
12. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
Usman MS; Siddiqi TJ; Anker SD; Bakris GL; Bhatt DL; Filippatos G; Fonarow GC; Greene SJ; Januzzi JL; Khan MS; Kosiborod MN; McGuire DK; Piña IL; Rosenstock J; Vaduganathan M; Verma S; Zieroth S; Butler J
J Am Coll Cardiol; 2023 Jun; 81(25):2377-2387. PubMed ID: 37344038
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
Wanner C; Marx N
Diabetologia; 2018 Oct; 61(10):2134-2139. PubMed ID: 30132035
[TBL] [Abstract][Full Text] [Related]
14. Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease.
Chan JSK; Perone F; Bayatpoor Y; Tse G; Harky A
Expert Opin Pharmacother; 2023 Jun; 24(8):935-945. PubMed ID: 37070470
[TBL] [Abstract][Full Text] [Related]
15. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
Thomson SC; Vallon V
Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
[TBL] [Abstract][Full Text] [Related]
16. Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
Qiu M; Ding LL; Zhan ZL; Zhou HR
Eur J Intern Med; 2021 May; 87():98-99. PubMed ID: 33485738
[No Abstract] [Full Text] [Related]
17. SGLT2 inhibition and heart failure-current concepts.
Custodio JS; Duraes AR; Abreu M; Albuquerque Rocha N; Roever L
Heart Fail Rev; 2018 May; 23(3):409-418. PubMed ID: 29704192
[TBL] [Abstract][Full Text] [Related]
18. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors.
Mordi IR; Lang CC
Heart Fail Clin; 2022 Oct; 18(4):529-538. PubMed ID: 36216483
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes.
Singhal R; Hechanova LA
Curr Cardiol Rep; 2022 Mar; 24(3):183-189. PubMed ID: 35147891
[TBL] [Abstract][Full Text] [Related]
20. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
Aguilar-Gallardo JS; Correa A; Contreras JP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
